Case Analysis : Pfizer Inc.

If one hold a key to resolve a very serious problem, one has a responsibility to put an effort to make it happen, at least try one’s best. In this case, river blindness disease was a very serious problem, and Dr. Vagelos was the one who could make a decision as to whether the research and development of a human version of ivermectin should be carried on, then it was his responsibility to pursue it.

First established in 1668 in Darmstadt, Germany, Merck is currently (in 1978) one of the largest prescription drug producers in the world. After coming off a 10 year drug drought in the late 1970s, Merck put a large amount of money into research to continue its dominance in the prescription drug industry. The research-first approach worked and since then Merck has increased sales significantly. Merck’s mission was well stated by founder George W. Merck. “We try never to forget that medicine is for the people…not for the profits” (Bollier 3).

New opportunities always exist in the healthcare industry, and Pfizer can be well-positioned to take advantage of these opportunities. It recently acquired Vicuron Pharmaceuticals which gave it instant access to that company's two major antibiotics. In addition, the company's pipeline includes inhalable insulin—likely to be a popular alternative to the injectable form. The company also continues to actively support its over-the-counter mouthwash—Listerine—classified as a "drug" because of its antiseptic properties (McTigue Pierce, 2005).

Recently Johnson & Johnson Pharmaceutical Company have been battling law suits stemming from the sale of their transvaginal mesh. This mesh offers relief to females suffering from pelvic organ prolapse, which constitutes a number of undesirable symptoms within the bowel region. Washington and California are the two states claiming damages against Johnson & Johnson and claim the Pharmaceutical Company misrepresented the risks associated with this device. Some patients have experienced irreversible complications associated with urinary dysfunction, loss of sexual function, constipation, and severe pain.

Pfizer is one of the world’s largest research-based pharmaceutical and biomedical companies that is dedicated to discovering, developing, manufacturing, and marketing prescription medications for both humans and animals. Pfizer was founded by cousins Charles Pfizer and Charles Erhart in 1849. Its top prescription products include Lipitor, Celebrex, and Lyrica, Prevnar, Viagra, Enbrel, Zyvox, and Norvasc.

Pfizer went global in 1951 in countries including Belgium, Canada, England, and Mexico, becoming instantly successful through direct immersion of its employees in

Unlike Gilead that has only one product in its Oncology line, Bristol-Myers Squibb presently have four different drugs namely: Erbitux –an epidermal growth factor receptor (EGFR) antagonist for the treatment of Head & Neck cancer and Colorectal cancer,(2) Opdivo (nivolumab) for the treatment of unresectable or metastic melanoma and lungs cancer, (3) Syrcel( dasatinb) for the treatment of newly diagnosed adult with Philadelphia chromosome –positive (ph+) chronic myeloid leukemia and (4) Yervoy (ipilimumob) for the treatment of melanoma a type of skin cancer that spread and as such cannot be remove by surgery. Like Seattle Genetics, the company products use either Antibody-drug Conjugate (ADC) though in a different version by linking potent cytotoxic to monoclonal antibodies targeted to specific tumor cells or immune-oncology, an innovative technology that unlocks the body own immune system to fight against cancerous cells. It also expanded its focus to Nolch inhibitor (used in blocking powerful pathway that promotes tumor cell survival for certain other types of cancer. (Bristol-Myer Squibb, 2014) Because the technology is similar but used differently, BMS would be considered a close competitor who currently has the advantage of having four targeted specific drugs and 12 other oncology and immune-oncology in various trial phases.

Founded in 1886 and represented among the Fortune 500, The Johnson & Johnson company is well-known for being a consumer of packaged goods, pharmaceutical, and an American multinational medical device manufacturing company (SCW, 2013).

First, identification of the strategies used by P&G is relevant to the discussion of its maintenance of its position or its loss of luster. The essence of a differentiation strategy encompasses developing the unique nature of the product or business to attract and retain its customers (Rothaermel, 2015). Procter & Gamble, via information contained in its marketing releases, pursues quality and value in its consumer goods offerings(Proctor & Gamble, 2017). According to P&G, it is directing significant resources towards research and development. Additionally, P&G prioritizes an emphasis on uniqueness of its products. This focus drives pricing and promotion. Among P&G’s product lines, it uses different strategies. P&G uses a primary strategy of market penetration. The firm executes this strategy with the goal of increasing its market share. Through marketing campaigns aimed at increasing consumer awareness of its products, P&G makes comprehensive and beneficial (incentive-laden) agreements with retailers to place its products in prominent locations

Pfizer, one of the largest pharmaceutical companies in the world, owned by CEO Ian C. Read has proven itself to be a controversial company as it headlines one of America’s largest industry. Making a huge revenue of over fifty billion dollars a year, the company dominates its industry here in the United States, second to none. Taken over in 2010 by Ian C. Read, the company has only grown and they continue to do that throughout 2017. Their journey to the top really began in 2000 when the company made their first major merge. Pfizer merged with Warner-Lambert, another company in the industry. 3 Years after that, Pfizer merged with Pharmacia and then in 2009 Wyeth. These three transactions made by Pfizer led them to skyrocket to the top of the food chain. With the company being so profitable in a controversial industry, Pfizer is often subject to various disputes and negative feelings toward the company. Pfizer has dealt with numerous lawsuits and have even been responsible for the deaths of many users who have used their products. Ian C. Read and Pfizer are “Robber Barons” due to these reasons.

GlaxoSmithKline company, formed when Glaxo merged with SmithKline in 2000. The purpose of the merger intensifying efforts in research and development of excellence for the development of drugs and treatment. GSK since integration become a leader in innovation and development of pharmaceutical and distribution companies, where the company has secured drugs AIDS in developing countries at reduced prices, also has provided treatments for other diseases at an affordable price for people in the poorest countries of the world.

At Pfizer, were inspired by a single goal: your health. That’s why we’re dedicated to developing new, safe medicines to prevent and treat the world’s

The Johnson & Johnson Company is focused on delivering products to warehouses and whole sellers and then distributing the products out to retailers. In order for this function to be as effortless and efficient as possible it is essential that the best candidates are trained thoroughly to interact with selected team members in order for the company to thrive. There are different level tiers of managers needed for the company, each has their role and importance to the successful implementation of the company’s objectives.

Regulations not only threaten to interfere with Pfizer 's international business, but are also imminent for its business in the United States. With the FDA having increased regulatory power, Pfizer 's costs are

With the acquisition of Wyeth, Pfizer was provided with an influx of 17 new drugs and vaccines including Effexor and Enbrel followed with the launch of five new drugs in 2013, such as Axitinib (for kidney cancer treatment); Tofacitinib (arthritis) and Prevnar (pneumonia), among others. These launches and influx should help Pfizer compete with more